

Lawrence S Honig

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7038605/publications.pdf>

Version: 2024-02-01

83
papers

8,886
citations

159525

30
h-index

88593

70
g-index

93
all docs

93
docs citations

93
times ranked

12231
citing authors

#	ARTICLE	IF	CITATIONS
1	Wolframin is a novel regulator of tau pathology and neurodegeneration. <i>Acta Neuropathologica</i> , 2022, 143, 547-569.	3.9	22
2	Anterolateral entorhinal cortex volume is associated with memory retention in clinically unimpaired older adults. <i>Neurobiology of Aging</i> , 2021, 98, 134-145.	1.5	5
3	Early Selective Vulnerability of the CA2 Hippocampal Subfield in Primary Age-Related Tauopathy. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 102-111.	0.9	35
4	Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study. <i>Alzheimer's and Dementia</i> , 2021, 17, 1353-1364.	0.4	160
5	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. <i>Nature Genetics</i> , 2021, 53, 294-303.	9.4	198
6	Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2021, 20, 182-192.	4.9	74
7	Olfactory Impairment Is Related to Tau Pathology and Neuroinflammation in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 1051-1065.	1.2	25
8	Patterns of tau pathology identified with 18 F- ¹⁸ F PET imaging. <i>Alzheimer's and Dementia</i> , 2021, , .	0.4	12
9	The Longitudinal Early-onset Alzheimer's Disease Study (LEADS): Framework and methodology. <i>Alzheimer's and Dementia</i> , 2021, 17, 2043-2055.	0.4	34
10	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2021, 27, 1187-1196.	15.2	182
11	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. <i>Frontiers in Neurology</i> , 2021, 12, 805135.	1.1	12
12	Association of Leukocyte Telomere Length With Perceived Physical Fatigability. <i>Innovation in Aging</i> , 2021, 5, 206-206.	0.0	0
13	Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration. <i>Molecular Neurodegeneration</i> , 2020, 15, 57.	4.4	33
14	Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer's Disease Treated with Escalating Doses for up to 133 Weeks. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 967-979.	1.2	36
15	Tau and other proteins found in Alzheimer's disease spinal fluid are linked to retromer-mediated endosomal traffic in mice and humans. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	37
16	Solanezumab in-depth outcomes. <i>Alzheimer's and Dementia</i> , 2020, 16, e038028.	0.4	3
17	Gantenerumab in-depth outcomes. <i>Alzheimer's and Dementia</i> , 2020, 16, e038049.	0.4	2
18	Overview of dominantly inherited AD and top-line DIAN-TU results of solanezumab and gantenerumab. <i>Alzheimer's and Dementia</i> , 2020, 16, e041129.	0.4	4

#	ARTICLE	IF	CITATIONS
19	Amyloid and tau PET in sporadic early-onset Alzheimer's disease: Preliminary results from LEADS. <i>Alzheimer's and Dementia</i> , 2020, 16, e041613.	0.4	2
20	Increased white matter MRI T1 hypointensity volume in young-onset Alzheimer's disease patients is not accounted for by age or cardiovascular risk factors. <i>Alzheimer's and Dementia</i> , 2020, 16, e045577.	0.4	0
21	Plasma biomarkers A β 42, A β 40, and tau in Down syndrome dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, e045698.	0.4	0
22	Neurodegeneration in the Longitudinal Evaluation of Early Onset Alzheimer's Disease Study (LEADS) sample: Results from the MRI core. <i>Alzheimer's and Dementia</i> , 2020, 16, e046338.	0.4	0
23	Sex-associated differences in pathology burden in early-onset Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e046532.	0.4	2
24	Leukocyte Telomere Length Is Unrelated to Cognitive Performance Among Non-Demented and Demented Persons: An Examination of Long Life Family Study Participants. <i>Journal of the International Neuropsychological Society</i> , 2020, 26, 906-917.	1.2	6
25	Allele-specific DNA methylation is increased in cancers and its dense mapping in normal plus neoplastic cells increases the yield of disease-associated regulatory SNPs. <i>Genome Biology</i> , 2020, 21, 153.	3.8	23
26	Research criteria for the diagnosis of prodromal dementia with Lewy bodies. <i>Neurology</i> , 2020, 94, 743-755.	1.5	365
27	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. <i>Acta Neuropathologica Communications</i> , 2020, 8, 5.	2.4	27
28	Cerebrospinal fluid amyloid levels are associated with delayed memory retention in cognitively normal biomarker-negative older adults. <i>Neurobiology of Aging</i> , 2019, 84, 90-97.	1.5	4
29	Safety of the tau-directed monoclonal antibody BII092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. <i>Lancet Neurology</i> , The, 2019, 18, 549-558.	4.9	108
30	Lewy Body Dementia Association's Research Centers of Excellence Program: Inaugural Meeting Proceedings. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 23.	3.0	9
31	Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 180-190.	1.2	84
32	Predicting Cognitive Improvement in Normal Pressure Hydrocephalus Patients Using Preoperative Neuropsychological Testing and Cerebrospinal Fluid Biomarkers. <i>Neurosurgery</i> , 2019, 85, E662-E669.	0.6	19
33	Heritability and genetic variance of dementia with Lewy bodies. <i>Neurobiology of Disease</i> , 2019, 127, 492-501.	2.1	29
34	Genome-wide analyses as part of the international FTLT-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLT. <i>Acta Neuropathologica</i> , 2019, 137, 879-899.	3.9	90
35	ICP-11: DOES ACQUISITION TIME AFFECT THE RESULTS OF 18F-FLORBETABEN IMAGING?. <i>Alzheimer's and Dementia</i> , 2019, 15, P20.	0.4	0
36	Pathological correlates of brain arterial calcifications. <i>Cardiovascular Pathology</i> , 2019, 38, 7-13.	0.7	8

#	ARTICLE	IF	CITATIONS
37	A comprehensive screening of copy number variability in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2019, 75, 223.e1-223.e10.	1.5	13
38	Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2018, 378, 321-330.	13.9	795
39	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. <i>Lancet Neurology</i> , The, 2018, 17, 548-558.	4.9	97
40	Gene Therapy in Alzheimer Disease—It May Be Feasible, but Will It Be Beneficial?. <i>JAMA Neurology</i> , 2018, 75, 791.	4.5	7
41	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. <i>Lancet Neurology</i> , The, 2018, 17, 64-74.	4.9	195
42	P345: TELOMERE LENGTH IN HUMAN LEUKOCYTE SUBPOPULATIONS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1123.	0.4	0
43	P4073: IN ABSENCE OF DEMENTIA, COGNITIVE PERFORMANCE DOES NOT RELATE TO THE BIOMARKER OF LEUKOCYTE TELOMERE LENGTH: AN EXAMINATION OF LONG LIFE FAMILY STUDY PARTICIPANTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1462.	0.4	0
44	O50304: THE LEWY BODY DEMENTIA ASSOCIATION RESEARCH CENTERS OF EXCELLENCE PROGRAM: TOWARD OPTIMIZING CLINICAL CARE AND CLINICAL TRIAL INFRASTRUCTURE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1646.	0.4	0
45	LRP10 in α -synucleinopathies. <i>Lancet Neurology</i> , The, 2018, 17, 1032-1033.	4.9	11
46	Clinical Experience with Cerebrospinal Fluid A β 42, Total and Phosphorylated Tau in the Evaluation of 1,016 Individuals for Suspected Dementia. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 1417-1425.	1.2	23
47	Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 689-707.	1.2	15
48	Role of Amyloid- β 2 and Tau Proteins in Alzheimer's Disease: Confuting the Amyloid Cascade. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S611-S631.	1.2	102
49	Transethnic genome-wide scan identifies novel Alzheimer's disease loci. <i>Alzheimer's and Dementia</i> , 2017, 13, 727-738.	0.4	166
50	Diagnosis and management of dementia with Lewy bodies. <i>Neurology</i> , 2017, 89, 88-100.	1.5	2,805
51	Telomere length is longer in women with late maternal age. <i>Menopause</i> , 2017, 24, 497-501.	0.8	25
52	Frequency of GBA Variants in Autopsy-Proven Multiple System Atrophy. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 574-581.	0.8	47
53	Rare coding variants in PLGG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	9.4	783
54	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2017, 49, 214.e13-214.e15.	1.5	12

#	ARTICLE	IF	CITATIONS
55	Short telomere length is associated with renal impairment in Japanese subjects with cardiovascular risk. PLoS ONE, 2017, 12, e0176138.	1.1	16
56	Age and Sex Distributions of Age-Related Biomarker Values in Healthy Older Adults from the Long Life Family Study. Journal of the American Geriatrics Society, 2016, 64, e189-e194.	1.3	38
57	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. Neurobiology of Aging, 2016, 38, 214.e7-214.e10.	1.5	78
58	A novel Alzheimer disease locus located near the gene encoding tau protein. Molecular Psychiatry, 2016, 21, 108-117.	4.1	260
59	JAMA Neurology Clinical Challenge. JAMA Neurology, 2015, 72, 745.	4.5	0
60	A Pathological Perspective on the Natural History of Cerebral Atherosclerosis. International Journal of Stroke, 2015, 10, 1074-1080.	2.9	42
61	Rarity of the Alzheimer Disease-Protective <i>APP</i> A673T Variant in the United States. JAMA Neurology, 2015, 72, 209.	4.5	41
62	Heritability of telomere length in a study of long-lived families. Neurobiology of Aging, 2015, 36, 2785-2790.	1.5	61
63	O4-04-04: Pooled biomarker analyses of phase 2 studies of vanutide cridifcar vaccine (ACC-001) in mild-to-moderate and early Alzheimer's disease. , 2015, 11, P276-P277.		0
64	<i>PARK10</i> is a major locus for sporadic neuropathologically confirmed Parkinson disease. Neurology, 2015, 84, 972-980.	1.5	48
65	Low tobacco-related cancer incidence in offspring of long-lived siblings: a comparison with Danish national cancer registry data. Annals of Epidemiology, 2015, 25, 569-574.e3.	0.9	9
66	Mediterranean diet and leukocyte telomere length in a multi-ethnic elderly population. Age, 2015, 37, 24.	3.0	61
67	Personality Change and Gait Dysfunction. JAMA Neurology, 2015, 72, 597.	4.5	1
68	Subacute Imbalance in a Renal Transplant Patient. JAMA Neurology, 2015, 72, 1367.	4.5	2
69	Abstract T P419: Pathological Arterial Wall Correlates of Lumen-based Remodeling: Results From the Brain Arterial Remodeling Study. Stroke, 2015, 46, .	1.0	1
70	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Human Molecular Genetics, 2014, 23, 6139-6146.	1.4	178
71	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1394.	4.5	166
72	Soluble amyloid beta levels are elevated in the white matter of Alzheimer's patients, independent of cortical plaque severity. Acta Neuropathologica Communications, 2014, 2, 83.	2.4	39

#	ARTICLE	IF	CITATIONS
73	Absence of <i>C9ORF72</i> expanded or intermediate repeats in autopsy-confirmed Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 827-830.	2.2	24
74	Alzheimer's-related changes in non-demented essential tremor patients vs. controls: Links between tau and tremor?. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 655-658.	1.1	31
75	Determinants of cerebrovascular remodeling: Do large brain arteries accommodate stenosis?. <i>Atherosclerosis</i> , 2014, 235, 371-379.	0.4	27
76	Hippocampal Laminar Distribution of Tau Relates to Alzheimer's Disease and Age of Onset. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 315-324.	1.2	12
77	O4-10-02: PLASMA AB40 AND AB42 DECLINE WITH PROGRESSION OF DEMENTIA. , 2014, 10, P271-P271.		0
78	P3-342: MEDITERRANEAN DIET AND LEUKOCYTE TELOMERE LENGTH IN A MULTI-ETHNIC ELDERLY POPULATION. , 2014, 10, P755-P755.		2
79	Treatment of Alzheimer's Disease: Current Management and Experimental Therapeutics. <i>Current Translational Geriatrics and Experimental Gerontology Reports</i> , 2013, 2, 174-181.	0.7	11
80	Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. <i>Lancet Neurology</i> , The, 2012, 11, 241-249.	4.9	390
81	Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and A β accumulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 7327-7332.	3.3	230
82	Model-guided microarray implicates the retromer complex in Alzheimer's disease. <i>Annals of Neurology</i> , 2005, 58, 909-919.	2.8	362
83	Avoid or Embrace? Practice Effects in Alzheimer's Disease Prevention Trials. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	3